中國先鋒醫藥(01345.HK)公佈中期業績 純利增加124% 希弗全收益升45.2%
格隆匯8月27日丨中國先鋒醫藥(01345.HK)公佈，截至2021年6月30日止六個月，公司收益為人民幣6.86億元，較去年同期增加10.2%；毛利為人民幣3.78億元，較去年同期增加50.3%；期間純利為人民幣6810萬元，較去年同期增加124.0%；每股基本盈利為人民幣0.06元，中期股息每股0.056港元。
集團平均毛利率由上年同期的40.4%增加至於報吿期內的55.2%。集團透過提供綜合性營銷、推廣及渠道管理服務銷售的藥品的毛利率由上年同期的66.6%增加至於報吿期內的67.9%，主要由於毛利率較高的部分產品於報吿期內銷售比例有所增加所致。集團透過提供綜合性營銷、推廣及渠道管理服務銷售的醫療器械的毛利率由上年同期的25.2%增加至於報吿期內的52.1%，主要由於公司大幅提升了毛利率較高產品的銷售比重。集團透過提供渠道管理服務銷售的產品毛利率由上年同期的4.6%增加至於報吿期內的6.9%。
報吿期內，集團透過提供綜合性營銷、推廣及渠道管理服務的藥品收益為人民幣4.85億元，較去年同期增長56.7%，佔集團報吿期內收益70.7%。毛利為人民幣3.29億元，較去年同期增長59.8%，佔集團報吿期內毛利87.0%。
報吿期內，集團就銷售希弗全實現的收益為人民幣2.255億元，較去年同期增長45.2%。作為集團的暢銷產品之一，憑藉產品的品質優勢、良好的市場佈局及合理的營銷策略，希弗全過去幾年一直保持高速增長。去年由於受疫情期間醫院停診、就醫人數減少的影響，希弗全的銷量一度出現波動。報吿期內，集團也在透過對產品差異化特點的深入挖掘，做好渠道下沉的同時，嚴格貫徹專業學術推廣策略，積極拓展和深化臨牀專家網路，擴大希弗全的品牌影響力。
公司表示，隨着中國醫療體制改革進入深水區，醫藥行業正在逐步形成新的生態。傳統的研發、審評審批、定價體系正發生深刻的變化，醫藥市場正在面臨重大的結構性調整。總體來看，中國醫藥行業內部分化發展將是長期趨勢，有明確臨牀價值、能滿足臨牀需求的治療性產品將面臨更大的發展機遇。集團將繼續圍繞產品開發引進、深度挖掘產品營銷能力、合作共贏擴大產品市場覆蓋、適時透過併購方式充實產業鏈這幾方面（如有），在中國醫藥行業格局的變化中積極應對，鋭意進取，實現未來發展的新藍圖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
